MicroRNA-Based Therapies for Neurodegeneration

📖 Wiki Page

therapeutic914 wordssynced 2026-04-02

MicroRNA-Based Therapies for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">MicroRNA-Based Therapies for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Description</td>
</tr>
<tr>
<td class="label">miRNA Mimics</td>
<td>Double-stranded RNAs that restore deficient miRNA function</td>
</tr>
<tr>
<td class="label">miRNA Inhibitors</td>
<td>Single-stranded antisense oligonucleotides (antagomirs)</td>
</tr>
<tr>
<td class="label">miRNA Sponges</td>
<td>Transgenic expression to sequester specific miRNAs</td>
</tr>
<tr>
<td class="label">Seed Targeting</td>
<td>Blockade of miRNA seed region to inhibit family members</td>
</tr>
<tr>
<td class="label">miRNA</td>
<td>Target Disease</td>
</tr>
<tr>
<td class="label">miR-29</td>
<td>AD</td>
</tr>
<tr>
<td class="label">miR-124</td>
<td>AD/PD</td>
</tr>
<tr>
<td class="label">miR-132</td>
<td>AD</td>
</tr>
<tr>
<td class="label">miR-7</td>
<td>PD</td>
</tr>
<tr>
<td class="label">miR-153</td>
<td>AD/PD</td>
</tr>
<tr>
<td class="label">miRNA</td>
<td>Target Disease</td>
</tr>
<tr>
<td class="label">miR-29b</td>
<td>AD</td>
</tr>
<tr>
<td class="label">miR-155</td>
<td>AD/PD/MS</td>
</tr>
<tr>
<td class="label">miR-21</td>
<td>PD/ALS</td>
</tr>
<tr>
<td class="label">miR-9</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">miR-17-92 cluste

...

MicroRNA-Based Therapies for Neurodegeneration

Introduction

Microrna Based Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression post-transcriptionally. Dysregulation of specific miRNAs has been implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). miRNA-based therapeutics include miRNA mimics (to restore lost function) and miRNA inhibitors (antagomirs/antisense) to block pathological overexpression. These approaches offer precision targeting of disease pathways. [@femt2021]

Molecular Mechanism

miRNA-based therapies work through several mechanisms: [@junn2020]

Key Therapeutic Candidates

miRNA Mimics

miRNA Inhibitors (Antagomirs)

Disease-Specific Applications

Alzheimer's Disease

Key miRNA targets:

miR-29: Reduces BACE1 expression and [Aβ](/proteins/amyloid-beta) production
miR-107: Regulates BACE1 and AD progression
miR-124: Promotes neuronal differentiation
miR-132: [Tau](/proteins/tau) metabolism and neuronal survival

Approach: miRNA mimics to restore protective miRNAs, inhibitors to block pathological overexpression

Parkinson's Disease

Key miRNA targets:

miR-7: Suppresses α-synuclein translation
miR-153: Targets α-synuclein mRNA
miR-124: Protects dopaminergic [neurons](/entities/neurons)
miR-29: Modulates neuronal survival

Approach: miR-7 and miR-153 mimics show neuroprotection in models

Huntington's Disease

Key miRNA targets:

miR-9: Targets mutant [huntingtin](/genes/htt) and RE1 silencing transcription factor
miR-17-92: Modulates transcriptional dysregulation
miR-10b: Regulates brain-derived neurotrophic factor

Approach: Combination approaches targeting multiple pathways

Amyotrophic Lateral Sclerosis

Key miRNA targets:

miR-155: Modulates neuroinflammation
miR-9: Targets SOD1 and [TDP-43](/proteins/tdp-43)
miR-23a: Modulates SOD1 expression
miR-218: Motor neuron-specific regulator

Approach: Antagomirs to reduce pathological miRNA levels

Clinical Trials

Note: Most miRNA therapies remain in preclinical development for neurodegeneration

Biomarker Applications

miRNAs in cerebrospinal fluid (CSF) and blood serve as disease biomarkers:

Challenges and Solutions

Delivery

Challenge: [Blood-brain barrier](/entities/blood-brain-barrier) penetration
Solutions: Conjugation to targeting ligands, viral vectors, [exosomes](/entities/exosomes)

Specificity

Challenge: miRNA families share seed regions
Solutions: Seed-targeting blockers, isoform-specific approaches

Off-target Effects

Challenge: Single miRNA targets multiple mRNAs
Solutions: Tissue-specific delivery, miRNA sponges

Research Directions

Current research focuses on:

Engineered miRNA constructs with enhanced specificity
Targeted delivery using nanoparticles and exosomes
Combination therapies with small molecules
Biomarker development for patient stratification
Vector-based miRNA expression systems

External Links

[miRBase - miRNA Database](https://www.mirbase.org/)
[ClinicalTrials.gov - miRNA](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=mirna)
[PubMed - miRNA Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=microRNA+neurodegenerative+disease)

Background

The study of Microrna Based Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Investment Landscape

For detailed investment analysis, clinical trial pipeline, and key player profiles, see [RNA Therapeutics: Investment Landscape Analysis](/rna-therapeutics:-investment-landscape-analysis).

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Tatura R, et al, MicroRNA therapy for neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35606628/)

[femt S, et al, miR-29 in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33749632/)

[Junn E, et al, miR-7 and α-synuclein in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/31889133/)

[Wong G, et al, miRNA in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33788628/)

[Wang R, et al, miRNA-based therapeutics for Huntington's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36583395/)

[Bhattacharya A, et al, miR-124 and neurogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35421356/)

[Zhang Y, et al, miRNA delivery using exosomes (2021)](https://pubmed.ncbi.nlm.nih.gov/34480126/)

[Barbato C, et al, miRNA biomarkers in CSF (2020)](https://pubmed.ncbi.nlm.nih.gov/32976538/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

MicroRNA-Based Therapies for Neurodegeneration

MicroRNA-Based Therapies for Neurodegeneration

Introduction

MicroRNA-Based Therapies for Neurodegeneration

Introduction

Overview

Molecular Mechanism

Key Therapeutic Candidates

miRNA Mimics

miRNA Inhibitors (Antagomirs)

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis

Clinical Trials

Biomarker Applications

Challenges and Solutions

Delivery

Specificity

Off-target Effects

Research Directions

See Also

External Links

Background

Investment Landscape

Allen Brain Atlas Resources

References

Related Hypotheses